The rate of atrial fibrillation was also higher in RSV patients, although it depended on preexisting heart conditions and ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

As paediatric teams across Ontario prepare for the upcoming respiratory season, Halton Healthcare is proud to share an ...

Vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a 72% drop in newborns being hospitalized ...

Respiratory syncytial virus vaccine, adjuvanted, contains recombinant glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK's proprietary AS01 E ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Background and epidemiology: Respiratory syncytial virus (RSV) is a ubiquitous paramyxovirus that infects the ciliated epithelial cells lining the airways. Nasal epithelial cells are infected ...

MISSISSAUGA, ON, Nov. 25, 2022 /CNW/ - GSK has filed a New Drug Submission (NDS) to Health Canada for its respiratory syncytial virus (RSV) older adult vaccine candidate.

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Respiratory syncytial virus is common, is quite contagious and infects most kids before their second birthday — that is, it did before the COVID-19 pandemic happened.

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. "Respiratory ...

Across Canada, both influenza and respiratory syncytial virus (RSV) have been almost completely absent during the 2020/21 winter. [1] [1] Data from the Southern hemisphere showed the same phenomenon ...